Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

(2010) Vishal Ranpura et al.   ACTA ONCOLOGICA

Fluoropyrimidine-associated cardiotoxicity: revisited

(2009) M Wasif Saif et al.   Expert Opinion On Drug Safety

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and Initial Treatment of Venous Thromboembolism in Patients With Cancer

(2009) Michael B. Streiff   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib in RCC—expanded access equals expanded benefit?

(2009) Toni K. Choueiri et al.   Nature Reviews Clinical Oncology

Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

(2009) Markus Moehler et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Cisplatin-associated thrombosis

(2008) Mariam Jafri et al.   ANTI-CANCER DRUGS

Gemcitabine: vascular toxicity and prothrombotic potential

(2008) Constantin A Dasanu   Expert Opinion On Drug Safety

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

(2008) T. MEYER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

CONSORT for reporting randomised trials in journal and conference abstracts

(2008) Sally Hopewell et al.   LANCET